Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025

Bill Number

H.R. 4392

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-07-15: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-06-25T08:07:51Z

AI-Generated Summary

Purpose

The Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 aims to improve early detection and treatment of uterine fibroids—noncancerous growths in the uterus that can cause pain, heavy bleeding, and fertility issues—through research, grants, and education. It authorizes the Secretary of Health and Human Services (HHS) to fund programs that address these health concerns, particularly for underserved groups.

Key Provisions

• Research on Early Detection and Strategies (Section 2): HHS must conduct or support research to boost early identification and intervention for uterine fibroids. Based on this, HHS will develop evidence-based or evidence-informed strategies (practical guidelines backed by research) to promote early detection in doctor's offices and clinics. These strategies must be finalized quickly to support grant-funded programs.

• Grants to States for Programs and Awareness (Section 3): HHS may award grants to states to run programs focused on:
• Increasing early detection and intervention for uterine fibroids.
• Creating public awareness and education campaigns about symptoms, risks, and early treatment.
• Grant funds can cover:
• Screening procedures, such as advanced imaging scans (with payments for these services).
• Patient navigation services (help guiding patients through healthcare systems).
• Applying the strategies from Section 2 in healthcare settings.
• Improving access to clinics and doctors.
• Priority goes to states targeting areas with socially vulnerable populations (e.g., low-income or minority communities) at higher risk for fibroids.

• Additional Research Grants (Section 4): HHS may fund research, including clinical trials (controlled studies testing treatments), on:
• Differences in pain management during uterine fibroid surgeries, especially disparities (unequal treatment) affecting certain groups.
• Asherman's Syndrome (scarring inside the uterus that can cause infertility), intrauterine adhesions (abnormal tissue sticking together inside the uterus), and similar conditions as deemed relevant by HHS.

• Reporting Requirements (Section 5):
• Every 2 years starting 2 years after the first grants, HHS must report to Congress and post online summaries of grant program results.
• Every 2 years starting 2 years after enactment, HHS must report on research progress related to pain disparities and intrauterine conditions.

Significant Changes to Existing Law

This bill introduces new authorities for HHS without directly amending prior laws. It creates standalone programs for uterine fibroid research and state grants, filling gaps in federal support for this women's health issue, which previously lacked dedicated funding mechanisms. No existing statutes are referenced or altered.

Potential Impacts

• Government Agencies: HHS will gain responsibilities for research coordination, grant administration, and biennial reporting, potentially increasing workload and budget needs (funding details not specified in the bill).
• Citizens: Women, especially in vulnerable communities, may benefit from earlier screenings, better pain management, and awareness campaigns, leading to reduced health complications like infertility or severe pain. It could improve access to care in underserved areas without direct costs to individuals.
• International Relations: No direct impacts; the bill focuses on domestic U.S. health programs.

Main Stakeholders Affected

• Federal and State Governments: HHS oversees implementation; states apply for and manage grants.
• Healthcare Providers and Facilities: Clinics and hospitals gain support for screenings, navigation, and research participation.
• Patients and Communities: Primarily women of reproductive age affected by uterine fibroids, with emphasis on socially vulnerable groups (e.g., racial minorities, low-income individuals) facing higher risks and disparities.
• Researchers and Advocates: Universities, medical organizations, and women's health groups can access funding for studies on fibroids and related conditions.

Notable Legal, Constitutional, or Political Implications

• Legal: The bill uses standard grant-authorizing language under HHS's existing powers, with no new enforcement mechanisms or penalties. It promotes health equity by prioritizing vulnerable populations, aligning with anti-discrimination principles in federal health policy.
• Constitutional: No apparent challenges; it involves spending for public health, a congressional power under the general welfare clause.
• Political: Highlights bipartisan focus on women's health (introduced by a diverse group of representatives), potentially advancing discussions on gender-specific disparities without controversial elements like abortion. It could influence future funding for reproductive health amid ongoing debates on healthcare access.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Brown, Shontel M. [D-OH-11]

Cosponsors (54)

Rep. Clarke, Yvette D. [D-NY-9], Rep. Sewell, Terri A. [D-AL-7], Rep. Foushee, Valerie P. [D-NC-4], Rep. McClellan, Jennifer L. [D-VA-4], Rep. Velázquez, Nydia M. [D-NY-7], Rep. Fields, Cleo [D-LA-6], Rep. Kelly, Robin L. [D-IL-2], Rep. Dingell, Debbie [D-MI-6], Rep. Tlaib, Rashida [D-MI-12], Rep. Trahan, Lori [D-MA-3], Rep. Johnson, Henry C. "Hank" [D-GA-4], Rep. Ansari, Yassamin [D-AZ-3], Rep. Watson Coleman, Bonnie [D-NJ-12], Rep. Scott, David [D-GA-13], Rep. Thanedar, Shri [D-MI-13], Rep. Thompson, Bennie G. [D-MS-2], Rep. Krishnamoorthi, Raja [D-IL-8], Rep. Salinas, Andrea [D-OR-6], Rep. McIver, LaMonica [D-NJ-10], Rep. Carter, Troy A. [D-LA-2], Rep. Meng, Grace [D-NY-6], Rep. Wilson, Frederica S. [D-FL-24], Rep. Lee, Summer L. [D-PA-12], Rep. Simon, Lateefah [D-CA-12], Rep. Wasserman Schultz, Debbie [D-FL-25], Rep. Figures, Shomari [D-AL-2], Rep. Adams, Alma S. [D-NC-12], Rep. Khanna, Ro [D-CA-17], Rep. Underwood, Lauren [D-IL-14], Rep. Green, Al [D-TX-9], Rep. Tokuda, Jill N. [D-HI-2], Rep. Rivas, Luz M. [D-CA-29], Rep. Mannion, John W. [D-NY-22], Rep. Pressley, Ayanna [D-MA-7], Rep. Titus, Dina [D-NV-1], Rep. Latimer, George [D-NY-16], Rep. Kamlager-Dove, Sydney [D-CA-37], Rep. Waters, Maxine [D-CA-43], Rep. Fletcher, Lizzie [D-TX-7], Rep. Menendez, Robert [D-NJ-8], Rep. Hayes, Jahana [D-CT-5], Rep. Jayapal, Pramila [D-WA-7], Rep. McBath, Lucy [D-GA-6], Rep. Subramanyam, Suhas [D-VA-10], Rep. Walkinshaw, James R. [D-VA-11], Rep. Stanton, Greg [D-AZ-4], Rep. McClain Delaney, April [D-MD-6], Rep. Stevens, Haley M. [D-MI-11], Rep. Magaziner, Seth [D-RI-2], Rep. Torres, Ritchie [D-NY-15] and 4 more

Recent Actions

• 2025-07-15: Referred to the House Committee on Energy and Commerce.
• 2025-07-15: Introduced in House
• 2025-07-15: Introduced in House

Bill Versions

• Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 — issued 2025-07-15 — PDF (5 pages)